Services
Life Sciences Asset Valuation
Independent, rigorous valuations for transactions, fundraising and strategic decisions.
Valuation in life sciences requires far more than financial modelling. It demands a deep understanding of clinical development risk, regulatory pathways, competitive dynamics and commercial potential, supported by robust methodologies.
BDC provides independent, defensible asset valuations used in licensing, M&A, fundraising and internal portfolio decisions.
Methodologies
- →Risk-adjusted Net Present Value (rNPV)
- →Discounted Cash Flow (DCF)
- →Comparable transactions and market multiples
- →Option-based models for staged development assets
- →Sum-of-the-parts for diversified portfolios
Use Cases
- →Licensing and partnering negotiations
- →Venture capital and private equity fundraising
- →M&A and asset acquisition
- →Strategic portfolio review
- →Litigation support and expert witness
- →Board and management reporting
Our Approach
Our valuations are built to be independent and defensible. Every assumption — probability of success, development timeline, peak sales, discount rate — is made explicit, benchmarked against comparable assets and deals, and documented so it survives the scrutiny of a counterparty, an investor or your own board.
Because our team understands clinical development, regulatory pathways and commercial dynamics, the numbers are grounded in the science rather than applied to it. You receive not just a value, but the reasoning you need to defend it in a negotiation.
Need an independent valuation?
Tell us about your asset and timeline — we will propose the right approach.